Detalhe da pesquisa
1.
Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan.
Am J Nephrol
; 53(10): 675-686, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36404708
2.
Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies.
Am J Nephrol
; 53(10): 687-700, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36423588
3.
Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Haematologica
; 102(3): 466-475, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27810992
4.
Mechanistic assessment of DNA ligase as an antibacterial target in Staphylococcus aureus.
Antimicrob Agents Chemother
; 56(8): 4095-102, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22585221
5.
Bactericidal activity of ACH-702 against nondividing and biofilm Staphylococci.
Antimicrob Agents Chemother
; 56(7): 3812-8, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22547614
6.
Danicopan, an Oral Complement Factor D Inhibitor, Exhibits High and Sustained Exposure in Ocular Tissues in Preclinical Studies.
Transl Vis Sci Technol
; 11(10): 37, 2022 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36301553
7.
In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens.
Antimicrob Agents Chemother
; 55(6): 2860-71, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21464250
8.
Discovery and Development of the Oral Complement Factor D Inhibitor Danicopan (ACH-4471).
Curr Med Chem
; 27(25): 4165-4180, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31573880
9.
Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.
J Med Chem
; 50(2): 199-210, 2007 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-17228862
10.
One-step syntheses of nitrofuranyl benzimidazoles that are active against multidrug-resistant bacteria.
J Antibiot (Tokyo)
; 64(10): 667-671, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21811261
11.
Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).
J Med Chem
; 54(9): 3268-82, 2011 May 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-21425851
12.
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
Antimicrob Agents Chemother
; 51(4): 1259-67, 2007 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-17242152
13.
Small molecule inhibitors of E. coli primase, a novel bacterial target.
Bioorg Med Chem Lett
; 17(10): 2807-10, 2007 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17350255
14.
Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.
Bioorg Med Chem Lett
; 16(5): 1277-81, 2006 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16337789
15.
Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.
Bioorg Med Chem Lett
; 16(5): 1272-6, 2006 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16337791